Pfizer signs deal with Allogene to develop cancer cell therapyReutersSan Francisco-based Allogene specializes in cancer treatment by developing CAR T cell therapy for blood cancer and tumors. Servier and Allogene aim to start mid-stage studies in 2019 … Continue reading
Business Wire (press release)Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate …Business Wire (press release)Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS – Nasdaq: CLLS)… Continue reading
Cancer Therapy AdvisorImmunotherapy and the Risk of MyocarditisCancer Therapy AdvisorThe risk should not discourage patients with cancer from taking these potentially life-extending therapies. Combinations of immune checkpoint inhibitors have the poten… Continue reading
Business Insider |
They’re Back! After Selling Kite, Belldegrun And Chang Seek To Change Cancer Treatment Again
Forbes Kite’s product, Yescarta, was approved by the Food and Drug Administration last October, a type of therapy called CART (short for: chimeric antigen receptor T–cell). It costs $373,000 per patient, and involves a laborious process to re-engineer … A CEO who sold his last cancer drug company for $12 billion just got $300 million to do it againBusiness Insider Ex-Kite chiefs’ biotech to research ‘off-the-shelf’ CAR-Ts with Cellectispharmaphorum Former Kite Execs Team With Pfizer to Create Biotech Co. to Treat CancerLos Angeles Business Journal Endpoints News all 7 news articles » |
|
Pfizer (PFE) and Allogene Therapeutics Enter Pact for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
StreetInsider.com Pfizer Inc. (NYSE: PFE) and Allogene Therapeutics, Inc. (Allogene) today announced that the two companies have entered into an asset contribution agreement for Pfizer’s portfolio of assets related to allogeneic chimeric antigen receptor T cell (CAR T … |
STAT |
They built a game-changing cancer-killing therapy. Now they’re taking on a new kind of CAR–T therapy
STAT The two former Kite Pharma executives behind a game-changing cancer-killing technology 1 are launching their next act: a new company to develop a suite of so-called off-the-shelf CAR–T therapy assets, designed so that they do not need to be … Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno …Digital Journal |